You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5195 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - In Combination with Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - In Combination with Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - In Combination with Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - In Combination with Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - In Combination with Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - In Combination with Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
New
May 2025
Drug
Other Name(s): Tecentriq® SC
Updated
May 2025
Drug
Other Name(s): Tecentriq™
Mar 2024

Pages